



A Phase 1, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0022, a novel MET/CSF1R/SRC inhibitor, in Patients with Advanced Solid Tumors Harboring Genetic Alterations in *MET*

PHARMACY MANUAL
TPX-0022-01

This document contains confidential information belonging to Turning Point Therapeutics. Except as otherwise agreed to in writing, by accepting or reviewing this document, you agree to hold this information in confidence and not copy or disclose it to others (except where required by applicable law) or use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, Turning Point Therapeutics must be promptly notified.